Differences in verotoxin neutralizing activity of therapeutic immunoglobulins and sera from healthy controls

• Published in: Infection 1993-05, Vol.21 (3), p.140-145
• Main Authors: BITZAN, M, KLEMT, M, STEFFENS, R, MÜLLER-WIEFEL, D. E
• Format: Article
• Language: English
• Subjects: Adolescent; Adult; Aged; Bacterial Toxins - chemistry; Bacterial Toxins - immunology; Bacteriology; Biological and medical sciences; Blood - immunology; Child; Child, Preschool; Chromatography, Affinity; Enterotoxins - immunology; Escherichia coli; Fundamental and applied biological sciences. Psychology; Humans; Immunization, Passive; Immunoglobulin G - isolation & purification; Immunoglobulins - immunology; Infant; Microbiology; Middle Aged; Nerve Tissue Proteins; Neutralization Tests; Plasma - immunology; Shiga Toxin 1; Shiga Toxin 2; Vaccines, antisera, therapeutical immunoglobulins and monoclonal antibodies
• ISSN: 0300-8126; 1439-0973
• DOI: 10.1007/BF01710530

Intestinal infection by Escherichia coli O157 and other verotoxin (VT) producing E. coli has been increasingly recognized as an important factor for the causation of classic (enteropathic) hemolytic uremic syndrome (HUS) and hemorrhagic colitis (HC). Toxins most frequently involved are VT1 and VT2. As with other toxin-mediated diseases, administration of immunoglobulin (Ig) may be beneficial. However, little is known about the immune response elicited by the toxin(s), and the prevalence of VT neutralizing antibodies in the healthy population. We studied the capacity of seven Igs and a commercial plasma preparation to neutralize four different VTs (VT1, VT2, VT2c and VT2e). The results were compared with the neutralization titers (NT50%) of normal human serum samples from various age groups. Plasma products and normal sera were separated by protein G affinity chromatography to investigate the factor(s) responsible for VT neutralization. All Igs neutralized VT1 (8 to 96 NT50%). None of them inhibited VT2, VT2c or VT2e effectively. In contrast, none of 40 pediatric, and only one of 20 adult control sera (starting dilution 1:4) neutralized VT1 (25 NT50%). All 60 samples as well as the plasma preparation blocked VT2 (22 to 446 NT50%, median 137), but not VT2c and VT2e. The VT1 neutralizing activity was eluted with the IgG fraction. The VT2 neutralizing activity was not bound by protein G, but was recovered in the IgG-free effluent. In conclusion, therapeutic Igs significantly neutralize VT1, but are largely ineffective against other VTs. In contrast, all control sera inhibited VT2, but rarely VT1.